Stoke Therapeutics, Inc.
STOK
$9.66
$0.303.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 15.01% | -1.99% | 1.33% | -9.67% | -3.59% |
| Total Depreciation and Amortization | -11.83% | -7.29% | 7.57% | 28.43% | 59.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.31% | 3.35% | 3.85% | 4.49% | 10.40% |
| Change in Net Operating Assets | -366.67% | -2.02% | 45.97% | 65.79% | -114.02% |
| Cash from Operations | -7.13% | -1.83% | 8.71% | 1.68% | -154.40% |
| Capital Expenditure | 87.44% | 78.29% | 80.54% | 55.48% | 59.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -199.73% | -180.66% | -128.41% | -56.03% | 356.59% |
| Cash from Investing | -201.44% | -182.28% | -129.40% | -56.05% | 330.91% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 147.31% | 201.64% | 185.82% | -80.25% | 14.22% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 147.31% | 201.64% | 185.82% | -80.25% | 14.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -181.19% | -152.18% | -98.86% | -111.07% | 348.53% |